Thank you for joining us at EADV, where we had the pleasure of connecting with industry leaders, innovators, and enthusiasts like you. It was an incredible opportunity to share insights, showcase our products and solutions, and forge valuable connections.
But the excitement doesn’t end in Berlin. In fact, it’s just the beginning! We’ve created this exclusive page to keep the momentum going and offer you an extended experience. Here, you’ll find ways to:
Scroll down, explore, and make the most of your post-show experience with us, or reach out to us HERE
Thank you for being part of our experience at EADV. Together, we’re shaping the future of phototherapy. Let’s continue this exciting journey!
Clinics should consider phototherapy as an invaluable addition to their services due to its proven effectiveness in treating various skin conditions such as psoriasis, eczema, and vitiligo. Phototherapy is a safe, non-invasive option with minimal side effects, making it suitable for a wide range of patients, including those who can’t tolerate other treatments. It not only enhances patient care but also expands the clinic’s treatment portfolio, attracting a diverse patient demographic. With the potential for increased revenue and improved patient satisfaction, opting for phototherapy is a smart move for any forward-thinking clinic looking to provide comprehensive and effective healthcare solutions.
Narrow Band UVB phototherapy is considered a first-line treatment for many conditions such as psoriasis, vitiligo and eczema, is safe enough for pregnant women and children to use, and has none of the serious side effects associated with competing biological drug therapies. And, Daavlin devices utilize our patented ClearLink Control System – a proprietary control system that consistently monitors the patient’s treatments and ensures accuracy and safety for every treatment.
Phototherapy leads other treatments in both effectiveness and speed of clearance. Narrowband UVB and PUVA (Psoralen + UVA) are safe, work extremely well, and are twice as fast at clearing patients with moderate to severe psoriasis.
1 Palmer, et al. Photoadaptation during Narrowband Ultraviolet-B Therapy Is Independent of Skin Type: A Study of 352 Patients Journal of Investigative Dermatology (2006) 126, 1256–1263
2 Yones, et al. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006 Jul;142(7):836-42.
3 ENBREL® Physician Package Insert. Available at: http://www.enbrel.com/pdf/enbrel_pi.pdf
4 HUMIRA® Prescribing Information. Available at: http://www.rxabbott.com/pdf/humira.pdf
5 REMICADE® Prescribing Information. Available at: http://www.remicade.com/remicade/assets/HCP_PPI.pdf
6 Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris, Walters, et al. Journal of the American Academy of Dermatology, Volume 40, Issue 6, June 1999, Pages 893-900